Sum-Fu Chiang

Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients

Enumeration of circulating tumor cells (CTCs) has been proven as a prognostic marker for metastatic colorectal cancer (m-CRC) patients. However, the currently available techniques for capturing and enumerating CTCs lack of required sensitivity to be applicable as a prognostic marker for non-metastatic patients as CTCs are even more rare. We have developed a microfluidic device utilizing antibody-conjugated non-fouling coating to eliminate nonspecific binding and to promote the multivalent binding of target cells. We then established the correlation of CTC counts and neoplasm progression through applying this platform to capture and enumerate CTCs in 2 mL of peripheral blood from healthy (n = 27), benign (n = 21), non-metastatic (n = 95), and m-CRC (n = 15) patients. The results showed that the CTC counts progressed from 0, 1, 5, to 36. Importantly, after 2-year follow-up on the non-metastatic CRC patients, we found that those who had ≥5 CTCs were 8 times more likely to develop distant metastasis within one year after curable surgery than those who had <5. In conclusion, by employing a sensitive device, CTC counts show good correlation with colorectal neoplasm, thus CTC may be as a simple, independent prognostic marker for the non-metastatic CRC patients who are at high risk of early recurrence.

Concurrent colonic mucosa-associated lymphoid tissue lymphoma and adenoma diagnosed after a positive fecal occult blood test: a case report

BackgroundColonic lymphoma is an uncommon presentation of extranodal lymphoma. Colonic mucosa-associated lymphoid tissue lymphoma is a different entity from gastric mucosa-associated lymphoid tissue lymphoma, and very rare. The presentation and management of colonic mucosa-associated lymphoid tissue are highly variable in the literature.Case presentationWe report the case of a 59-year-old Taiwanese man who underwent a colonoscopy after a positive test for fecal occult blood. His past history included hypertension and hyperthyroidism. The colonoscopy revealed an adenomatous polyp and mucosa-associated lymphoid tissue lymphoma. We successfully performed a polypectomy and endoscopic mucosal resection. The lymphoma was staged according to the Ann Arbor system modified by Musshoff as E-I. Our patient showed no lymphoma recurrence over a 3-year follow-up.ConclusionsEndoscopic mucosal resection for colonic mucosa-associated lymphoid tissue lymphoma without disseminated disease may be feasible. We successfully used colonoscopic treatment without adjuvant therapy to treat early-stage pathogen-free colonic mucosa-associated lymphoid tissue lymphoma.

Impact of Diabetes Status on Long Term Oncological Outcome of Stage II Colorectal Cancer

目的 糖尿病與大腸直腸癌有相似的飲食及生活因子。目前許多研究均顯示糖尿病病患有較高的大腸直腸癌發生率及較差的總存活率，但是長期存活率及癌症相關存活率的研究卻相對有限且無一致的結論。方法 挑選本院1999 年至2002 年第二期大腸直腸癌接受根除性切除但排除接受放射治療之病患。比較糖尿病及非糖尿病病患之臨床病理表現、長期總存活率及癌症相關存活率，另外則比較不同糖尿病治療方式之癌症相關存活率之異同。結果 在大腸直腸癌病患中，罹患糖尿病的病患有較高的年齡、BMI、慢性腎衰竭 (19%vs. 7.5%, p ＜ 0.001)、心肌梗塞 (16.7% vs. 5.7%, p = 0.043)、心衰竭病史 (4.8% vs. 1.2%, p= 0.008) 及癌胚抗原數值 (CEA ＞ 5 ng/ml, 55.2 vs. 33.6%, p ＜ 0.001)。兩組間總體存活率並無顯著差異，但糖尿病病患比非糖尿病病患有顯著較高的5 年癌症相關存活率 (91%vs. 81%, p = 0.025) 及3 年疾病無復發率 (88% vs. 78%, p = 0.015)。在多變數分析中排除metformin 使用及其他因子後糖尿病仍有顯著較低之疾病復發率風險 (HR = 0.192, p =0.023)，然而多變數分析中糖尿病之癌症死亡率風險卻達邊緣性統計顯著 (HR = 0.258, p= 0.064)。結論 糖尿病在第二期大腸直腸癌病患中雖有較高的癌胚抗原值，但排除metformin 使用後糖尿病對於第二期大腸直腸癌之癌症預後為明顯保護因子。

Neoadjuvant Long Course CCRT Significantly Increases Disease Free Survival among Pathological Stage III Rectal Cancer Patients as Compared to Short Course RT Alone

目的 對於局部晚期直腸癌的病患，為了達到更好的局部控制及存活率，無論是術前短程放射治療或是長程同步放化療皆被使用中。然而，如何選擇這兩個治療方法仍無定論。方法 我們蒐集了2002 年1 月1 日至2006 年12 月31 日於林口長庚醫院診斷為局部晚期直腸癌的病患，所有病患皆接受完整術前短程放射治療或是長程同步放化療並接受根除性手術，術後追蹤日期至2009 年12 月31 日。變異項目如病患的性別、年齡、術前CEA 濃度及腫瘤位置皆被收集分析。總生存率，無病生存率，局部復發率和遠處轉移率也由統計分析比較。結果 在臨床病理特徵方面，腫瘤位置是短程治療及長程治療唯一的差異項 (低位直腸63.4% vs. 81.0%, p = 0.049)。針對淋巴結轉移與否的次族群分析存在許多統計上的差異。對於沒有淋巴結轉移的次族群，短程治療有較好的總生存率 (五年存活率89.3% vs. 62.2,p = 0.009)。對於有淋巴結轉移的次族群，長程同步放化療則有較好的無病生存率 (五年存活率27.8% vs. 64.7%, p = 0.018)，較低的遠處轉移率 (Metastasis free rate 26.8% vs.76.5%, p = 0.003) 及趨向有較好的總生存率 (p = 0.059)。對於局部復發率，兩者並無顯著差異 (83.0% vs. 87.5%, p = 0.557)。結論 基於我們的研究，對於中低位直腸癌且有淋巴結轉移的病患，為了達到更好的無病生存率，術前長程同步放化療是可以考慮的治療方式。對於沒有淋巴結轉移的病患，術前短程放療則與術前長程同步放化療有同樣的疾病控制。

Worse Survival in Rectal Cancer Patients with Preoperative Radiotherapy Compared to without Radiotherapy in Same Postoperative Pathologic pN1 Classification

Purpose. In this study, we compared the rectal cancer patients with and without preoperative radiotherapy, to evaluate the change of pathologic characteristics and prognosis. Patients and Methods. From 2002 to 2007, the cases of primary rectal cancer and receiving curative resection were selected. Totally, there were 1544 cases including 239 cases preoperative radiotherapy enrolled. Results. After preoperative radiotherapy, the significant change of pathologic characteristics included more percentage of smaller tumor size, ulcerative morphologic type and poor differentiation histological grade in patients with preoperative RT than those of not (all p ＜ 0.05). The recurrent incidence, 3-year disease-free and 5-year cancer-specific survival rates of patients with preoperative radiotherapy vs. no radiotherapy were 60.0 vs. 42.8% (p = 0.04), 45.0 vs. 59.7% (p = 0.04) and 47.6 vs. 64.3% (p = 0.056) in pT4 patients, and were 48.1 vs. 30.7% (p = 0.01), 52.8 vs. 72.9% (p ＜ 0.01) and 51.8 vs. 75.1% (p = 0.03) in pN1 patients, respectively. After curative resection of tumor, the prognosis of pN1 patients with preoperative radiotherapy was worse than those without radiotherapy. There was no difference in survival rate of pN0 and pN2 classification between the patients with and without preoperative RT. Conclusion. Downstage effect of preoperative RT has beneficial impact on long term survival of patients with rectal cancer, but our findings showed that the worse survival rates of pathologic ypN1 classification of patients with preoperative RT then pathologic pN1 classification without preoperative RT. This may be resulted from change of characteristics of cancer cell behavior or insufficient response to show benefits. Further study is necessary to more precisely select suitable patients for receiving preoperative RT.

Transanal Local Excision Versus Radical Surgery for T1N0 Lower Rectal Adenocarcinoma

Background. The aim of this study was to compare surgical outcomes including survival in T1N0 rectal adenocarcinoma patients undergoing transanal local excision or radical surgery. Methods. We retrospectively reviewed 87 and 176 patients who underwent transanal local excision and radical surgery, respectively, for T1N0 rectal adenocarcinoma without neoadjuvant chemotherapy or radiotherapy between May 1995 and January 2013. Results. The mean age, sex distribution, and carcinoembryonic antigen level were similar between the 2 groups. The mean duration of hospital stay was 4.66 days in the local resection group and 12.32 days in the radical surgery group (p＜0.05). The overall survival rate at 5 years was 91% in the local resection group and 83% in the radical surgery group (p=0.928). The disease-free survival rate at 5 years was 87% in the local resection group and 93% in the radical surgery group (p=0.037). The disease- free survival rate at 5 years in the local resection group was significantly poorer than in the radical surgery group. Conclusion. Local excision is an alternative method of treatment for early lower rectal adenocarcinoma. With selection, the oncologic outcomes for local excision are similar to that of radical surgery. Advantages of local excision include early bowel function recovery, shorter hospital length of stay, lower morbidity, and avoidance of colostomy.

Prognosis of Stage IIIA Colorectal Cancer Patients with or without Postoperative Adjuvant Chemotherapy

Introduction. The new definition of stage IIIA colorectal cancer (CRC) was introduced in the Seventh Edition of the American Joint Committee on Cancer (AJCC 7th). Because the outcomes of patients with stage IIIA CRC are not worse than those of patients with stage II disease, we evaluated whether chemotherapy would also benefit this group of patients.Patients and Methods. Patients who received curative surgery and were diagnosed with stage IIIACRC between 1995 and 2006 were enrolled and analyzed.Results. Total 149 patients diagnosed stage IIIA colorectal cancer were enrolled. In these patients, 31 were T1 stage with only one found recurrence. Whether adjuvant therapy performed or not, there was no significant meaning for their prognosis. For T2 patients, higher recurrence rate was noted with N1b patients. Though no statistical meaning achieved, for those without chemotherapy, mucinous type, insufficient lymph node exam, higher recurrent rate were noted. The new AJCC 7th made difference in T1N2a group. Though only 5 patients collected in this study, none was found tumor recurrence, and the result was compatible with the new staging system.Conclusion. Adjuvant therapy is recommended for stage IIIA CRC patients with T2 disease. However, adjuvant chemotherapy may not be beneficial for stage IIIA CRC patients with T1 disease.

A Colonic Submucosal Giant Lipoma Presenting with Intermittent Intussusception and Bleeding-A Case Report and Review of the Literature

Colonic lipoma with intussusception is rare. We report a case of colocolonic intussusception induced by a submucosal lipoma. A 51-year-old woman was diagnosed with colonic lipoma with suspected malignancy and gallstone. Definite diagnosis was made after laparoscopic extended right hemicolectomy and cholecystectomy. Clinical and pathologic features of colonic lipoma are then discussed.

Surgical Management for Stage I, II Anorectal Melanoma: An Experience of a Single Institution

Objective: The aim of our study was to determine whether APR (abdominoperineal resection) was the better choice for stage Ⅰ and stage Ⅱ anorectal melanoma. Methods: A retrospective study of 16 patients from Chang Gung Memorial Hospital between 1976 and 2007 was made. Ten of them had stage Ⅰ and stage Ⅱ diseases. We analyzed their surgical methods and outcomes. Results: Stage Ⅰ patients had a better outcome than stage Ⅱ patients. APR was the preferred curative surgical method for anorectal melanoma (stage Ⅰ, smaller tumor size, shallower invasion depth, and thinner tumor thickness). Conclusions: We recommend APR as curative surgery for stage Ⅰ anorectal melanoma with tumor size of less than 2 cm, tumor invasion depth not surpassing the submucosal layer, and tumor thickness of less than 8 mm.